Navigation Links
ViroPharma to Discuss Commercialization and Launch of Cinryze(TM) on November 5, 2008
Date:10/30/2008

- Conference Call to Be Held at 4:00 P.M. Eastern Time -

EXTON, Pa., Oct. 30 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) will host a conference call and live audio webcast at 4:00 p.m. Eastern Time on Wednesday, November 5, 2008 to discuss the commercialization plans and launch of Cinryze C1 Inhibitor (human), which has been recently approved by the U.S. Food and Drug Administration for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE.

The live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com. An audio archive will be available at the same address until November 20, 2008. To participate in the conference call, please dial (877) 366-0713 (domestic) and (302) 607-2000 (international). After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) (vancomycin hydrochloride capsules, USP), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains, and Cinryze(TM) (C1 inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, http://www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ViroPharma Incorporated Reports Third Quarter 2008 Financial Results
2. ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008
3. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
4. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
5. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
6. ViroPharma Provides Update on Vancocin(R)
7. ViroPharma Augments Senior Management
8. ViroPharma to Present at the 26th Annual JP Morgan Healthcare Conference
9. ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
10. ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results
11. ViroPharma to Present at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... Texas (PRWEB) , ... May 26, 2017 , ... Yisrayl ... a new publication this week that is focusing on the Peace Agreements being discussed ... his Middle East sprint in a race to try to speed up peace talks ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled oral surgeon ... informational blog post on insurance options. If a Bay Area patient has to search ... time and money. Visiting an in-network provider for a second opinion can ensure a ...
(Date:5/26/2017)... ... May 26, 2017 , ... Centennial-based ... of proceeds from its 14th Annual Clays for Kids fundraiser, to be held ... Bennett, Colorado. , As part of BluSky’s partnership with The Adoption Exchange, ...
(Date:5/26/2017)... ... May 26, 2017 , ... Water damage to the ... Jersey School District had left education officials with a number of critical issues to ... the flooring had to be accomplished with little or no disruption to class schedules. ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Alan I. Benvenisty, MD is ... York City. He is known for his distinguished expertise and experience in the diagnosis ... holds sub-specialty training in treating renovascular disease and aortic aneurysm . He is ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... May 4, 2017 Clarius Mobile Health, ... handheld ultrasound scanners this week at the American ... (ACOG) in San Diego, CA ... "Clarius is the perfect tool for clinicians to ... rate, and evaluate pregnancy-related complications like ectopic pregnancy ...
(Date:5/4/2017)... , May 4, 2017   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade hypothermic ... or the "Company"), today announced that the Company,s first ... close on Thursday, May 11, 2017, and that the ... at 1:30 p.m. PT that afternoon. Management will provide ...
(Date:5/3/2017)... 2017  West Pharmaceutical Services, Inc. (NYSE: WST), ... drug administration, announced today that Fran DeGrazio ... and Diane Paskiet , Director, Scientific Affairs, ... on West,s expertise in the areas of safety ... providing commentary on updated industry guidance. ...
Breaking Medicine Technology: